Skip to main
TXG
TXG logo

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 42%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics is poised for significant growth, driven by an increase in Chromium reaction volumes, which indicates a robust market presence despite ongoing pricing pressures in the industry. The company is projected to experience substantial growth in consumables revenue, with estimates suggesting a 5-19 times increase by 2027, outpacing instrument revenue growth. Additionally, a forecasted production growth of over 60% quarter-over-quarter and 50% half-over-half as Media Luna ramps up through 2026 supports a positive outlook for the company's future financial performance.

Bears say

10x Genomics (TXG) is facing significant challenges, including a contraction in revenue in 2024 driven by double-digit pricing pressure and flat to declining volume growth, with market recovery not anticipated until 2027. The company reported disappointing Q4 earnings, missing EPS expectations and providing a full-year revenue outlook that fell below analyst forecasts. Additionally, the stock has experienced a substantial decline of over 90% since its peak in 2021, indicating that market expansion has not met prior expectations.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 42% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Buy based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.